Pfizer And EpiPen Consumers Reach $345M Deal

By J. Edward Moreno · July 15, 2021, 6:29 PM EDT

Pfizer has reached a $345 million settlement with a class of consumers who allege they overpaid for EpiPens because of anti-competitive practices by pharmaceutical companies, potentially clearing the company from having...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By J.

February 15, 2022
CVS Wants Consolidated Drug Pricing Suit In Arbitration
February 04, 2022
Final Approval In Glumetza Antitrust Deal Gives Attys $50M
February 03, 2022
GAO Says VA Reasoning Was Sound In $735M IT Deal
January 24, 2022
Pharma Cos. Get Bystolic Generic Delay Claims Tossed
January 18, 2022
Teva, Glenmark Must Face Price-Fixing Suit At Same Trial
January 12, 2022
Sutter Antitrust Trial Must Go On Despite COVID, Judge Told
January 04, 2022
Generic Drug Cos., Takeda Escape Gout Drug Antitrust Suit
December 02, 2021
FTC Pushing Caris Life Sciences For Merger Challenge Docs
November 17, 2021
Consumer Counsel Gets $115M From EpiPen Settlement
November 10, 2021
FTC Judge Says Amici Offer Nothing New In Illumina Case